ABCG2 and chronic myelogenous leukemia, BCR-ABL1 positive: Tyrosine Kinase Inhibitors (TKIs), like nilotinib and dasatinib, are effective treatments available for Chronic Myeloid Leukaemia (CML) and found to interact with ABCB1 and ABCG2.